USA
Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease
On Monday, April 28, 2025, Vermont, Waterbury, wegovy injection items held in Vermont.
Shelby Knowles | Bloomberg | Getty Images
Novo Nordisk shares climbed approximately 5% on Monday after accelerating approval from the US Food and Pharmaceutical Administration to treat a serious liver disease of Wegovy Obesity, which broke the company’s box office records.
On Friday, the Company said that the approval of Steatohepatitis (MASH) associated with metabolic dysfunction (MASH) in adults with mid -liver fibrosis.
Novo Nordisk shares increased by 5.05% to London time (4:45 et) 09:59.
This is an developing story. Please check again for updates.
